Table 2.
Demographic, clinical, and laboratory parameters of the patients grouped by time-to-negative swab
| A: < 26 days | B: ≥ 26. ≤ 39 days | C: ≥ 39 days | p value | Linear-by-linear association | |
|---|---|---|---|---|---|
| Number of patients, n° (%) | 721 (74.9%) | 194 (20.1%) | 52 (5.4%) | ||
| Age, median (Q1–Q3) | 60 (50–70) | 64 (55–72) | 67 (57–77) | < 0.001b | < 0.001 |
| Males, n° (%) | 460 (63.8%) | 128 (67.3%) | 30 (57.7%) | 0.399a | 0.936 |
| Charlson Comorbidity index, median (Q1–Q3) | 2 (1–4) | 2 (1–4) | 3 (2–5) | 0.009c | 0.001 |
| Arterial hypertention, n° (%) | 329 (45.8%) | 114 (60%) | 23 (44.2%) | 0.02a | 0.51 |
| Cardiovascular disease, n° (%) | 170 (23.6%) | 60 (31.5%) | 19 (36.5%) | 0.017a | 0.005 |
| Chronic obstructive pulmonary disease, n° (%) | 49 (6.9%) | 19 (10%) | 6 (11.5%) | 0.194a | 0.074 |
| Chronic kidney disease, n° (%) | 36 (5%) | 23 (12.2%) | 5 (9.6%) | 0.001a | 0.002 |
| Cancer, n° (%) | 41 (5.7%) | 17 (8.9%) | 2 (3.8%) | 0.199a | 0.537 |
| Chronic liver disease, n° (%) | 25 (3.5%) | 10 (5.3%) | 2 (3.8%) | 0.642a | 0.721 |
| Diabetes, n° (%) | 132 (18.3%) | 43 (22.6%) | 14 (26.9%) | 0.168a | 0.059 |
| Dementia, n° (%) | 22 (3.1%) | 6 (3.2%) | 3 (5.8%) | 0.551a | 0.4 |
| Fever, n° (%) | 430 (60%) | 119 (63.3%) | 31 (60.8%) | 0.473a | 0.967 |
| Dispnea, n° (%) | 484 (67.6%) | 136 (72.3%) | 34 (66.6%) | 0.442a | 0.505 |
| Astenia, n° (%) | 177 (24.8%) | 53 (28.2%) | 19 (37.2%) | 0.116a | 0.48 |
| Cough, n° (%) | 229 (32%) | 66 (35.1%) | 20 (39.2%) | 0.455a | 0.212 |
| Patients with severe outcome of COVID-19 n° (%) | 158 (22%) | 51 (26%) | 16 (30.7%) | 0.232a | 0.046 |
| Days from last positive to first negative, median (Q1–Q3) | 5 (2–8) | 6 (4–10) | 7 (4–13) | < 0.001c | < 0.001 |
p < 0.05 were written in Bold
aChi-square test
bt-student test
cMann–Whitney test